Intratumoral Combo Shrinks Melanomas Refractory to Anti-PD-1
Intratumoral injection of an investigational agent, BO-112, combined with pembrolizumab (Keytruda) demonstrated promising efficacy in certain patients with advanced melanoma refractory to anti-PD-1-based therapy, according to results from a single-arm phase II trial. Ten of 40 evaluable patients responded to treatment — six partial and four complete responses — meeting the study’s primary endpoint of […]
Add-on Pembrolizumab Tied to Good QoL in Women With Advanced Cervical Cancer
PHOENIX — The addition of pembrolizumab (Keytruda) to chemotherapy, with or without bevacizumab (Avastin), in women with persistent, recurrent, or metastatic cervical cancer was linked with better quality of life (QoL), a researcher reported. Patient-reported outcomes (PRO) from the KEYNOTE-826 trial showed that changes from baseline in QLQ-C30 global health status (GHS)/QoL scores — a […]
FDA OKs PD-1 Inhibitor for Adjuvant Treatment of Kidney Cancer
The FDA approved pembrolizumab (Keytruda) for the adjuvant treatment of renal cell carcinoma (RCC) for patients who have an intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions, the agency announced. Approval was based on results from the KEYNOTE-564 trial, which demonstrated that adjuvant pembrolizumab following nephrectomy significantly […]
Practice-Changing Study in Advanced Cervical Cancer
Adding pembrolizumab (Keytruda) to chemotherapy with or without bevacizumab (Avastin) significantly slowed progression of metastatic cervical cancer and improved overall survival (OS), investigators in a randomized trial concluded. Median progression-free survival (PFS) improved from 8.2 months with chemotherapy plus or minus bevacizumab (Avastin) to 10.4 months with the addition of the PD-1 inhibitor. Comparison of […]
Adjuvant Pembrolizumab Boosts Recurrence-Free Survival in High-Risk Melanoma
Adjuvant pembrolizumab (Keytruda) for resected stage II melanoma significantly prolonged recurrence-free survival (RFS) compared with placebo, according to results from the KEYNOTE-716 trial. At a median follow-up of 14.4 months, pembrolizumab for resected stage IIB and IIC melanoma decreased the risk of disease recurrence or death by 35% compared with placebo (hazard ratio 0.65, 95% […]